Efficacy of Subantimicrobial Dose XXXX for Moderate-to-Severe and Active Graves' Orbitopathy.

@entity1 @entity2743 @entity3403 @entity5768 @entity892 @entity922
Aim. To study the efficacy and safety of subantimicrobial dose (SD) @entity3403 (50   mg/d) in @entity1 with active and moderate-to-severe @entity2743 ( @entity2743 ). Methods. Thirteen @entity1 with active and moderate-to-severe @entity2743 received once daily oral @entity3403 (50   mg/d) for 12   wk. Treatment response at 24   wk was used as the primary outcome, measured by a composite of improvement in @entity922 ( @entity922 ), @entity892 , motility, soft tissue swelling, @entity5768 , and eyelid aperture. Secondary outcome was the change of quality of life score (QoL, including visual functioning subscale and appearance subscale). Adverse events were also recorded. Results. Overall improvement was noted in eight out of 13 @entity1 (61.5%, 95% CI 31.6%-86.1%). Both @entity922 and soft tissue swelling significantly ameliorated in eight @entity1 at 24   wk. Five @entity1 (38.5%) had improvement in ocular motility of >= 8 degrees. Eyelid aperture (46.2%) also decreased remarkably. For QoL, a significant improvement in appearance subscale (P = 0.008) was noted during the study, whereas no difference was observed in visual functioning subscale (P = 0.21). Two @entity1 reported mild stomachache at 12   wk. Conclusions. SD @entity3403 appears to be effective and safe for the treatment of active and moderate-to-severe @entity2743 . It might serve as a new promising therapeutic strategy for @entity2743 . This trial is registered with NCT01727973.
